Lawrence P. Wennogle

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY.

Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ.